Ambrosia Biosciences
Develops orally delivered, small molecule-based therapies for obesity and other metabolic disorders
$100MSeries B
Role not disclosedBO
Blue Owl Healthcare Opportunities
Activity from announced rounds
Activity in this selectiondieter-von-holtzbrinck-ventures-91bc3d2f
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $350M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionMirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosed